Patricia Van Arnum

Editorial Director, DCAT

patricia@dcat.org
Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members. She is editor of DCAT Value Chain Insights, DCAT’s editorial newsletter providing news and analysis of the business of bio/pharmaceutical development and manufacturing covering the full spectrum of the bio/pharmaceutical manufacturing value chain. She also provides content advisement and support for DCAT’s volunteer committees. Overall, she has more than 25 years of experience covering the Bio/Pharmaceutical, Fine-Chemical and Chemical industries as a business and science editor. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science and holds undergraduate degrees in chemistry, economics, and political science.

LATEST

Teva’s President and CEO Launches New Pivot to Growth Strategy
By

By
Teva’s President and CEO, Richard Francis, who assumed the helm of Teva in January, outlined this week the company’s new strategic framework to drive growth. The company’s Pivot to Growth strategy encompasses four main pillars to deliver short- and long-term growth from the company’s commercial portfolio and biosimilars, innovative pipeline, generics business, and focused capital allocation. 

Tackling Drug Shortages and Supply-Chain Vulnerabilities in the European Union
By

By
Leaders in the European Union (EU) are addressing ways to mitigate drug shortages and supply-chain vulnerabilities in the EU with 19 EU member states supporting a Critical Medicines Act to reduce the EU’s dependence of non-EU countries for APIs, intermediates and other pharma ingredients. What other actions is the EU taking to mitigate supply-chain vulnerabilities?

CDMOs/CMOs: A Roundup of the Latest Expansions in Biomanufacturing
By

By
Several CDMOs/CMOs are proceeding with large-scale investments in new biomanufacturing facilities as biologic drug-substance manufacturing continues to be an active area of investment among CDMOs/CMOs. What companies are expanding production capacity? 

AI & Drug Mfg: Industry Gives Input on FDA’s Discussion Paper
By

By
The bio/pharma industry and other stakeholders have provided input on a recent FDA discussion paper on artificial intelligence (AI) in drug manufacturing as the agency considers a regulatory framework and issues to consider when overseeing AI-based drug manufacturing.

Blockbuster Watchlist: Which New Drugs Have the Best Potential?
By

By
What are the blockbusters of the future? A recent industry analysis points to the leading contenders from late-stage or newly approved drugs that are slated to launch in 2023 and that are poised for potential blockbuster status over the next five years. Which drugs are the leading contenders?

What’s the Verdict: Industry Weighs in on the EU’s Proposed Pharma Reforms
By

By
The European Commission’s proposal to revise the EU’s pharma legislation includes changes for market exclusivity, further incentives and support for innovation, and measures to increase availability of both innovator and generic drugs. What does the industry think?

Executive Insights: GSK’s Sustainable Procurement Program for Suppliers
By

By
Lisa Martin, Senior Vice President, Global Procurement, and Chief Procurement Officer, GSK, discusses the company’s Sustainable Procurement Program for Suppliers and how the company is working with suppliers to meet its sustainability targets. 

API Alert: EU Proposes New Requirements To Secure Pharma Supply Chains
By

By
The European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages and secure supply chains. 

Pharma Industry Outlook: Where is the Growth?
By

By
Graham Lewis, Vice President, Global Pharma Strategy, IQVIA, gave a bio/pharma market overview at DCAT Week and outlined what lies ahead for the industry. 

Executive Views: Supply-Chain Disruptions & Operational Resilience
By

By
PwC’s bi-annual Global Crisis and Resilience Survey reveals companies and business leaders overestimate their resilience despite operating in a period of supply disruption.